Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prasugrel versus placebo in pediatric sickle cell disease
2012-003837-41Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in sickle cell disease (SCD) comparing Prasugrel with Placebo (2 arms). Primary endpoint: Rate of vaso-occlusive crisis. Started Jan 2013; status: completed.
02
Drugs
prasugrel
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2012-003837-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003837-41.